Myriad Genetics FQ2 top line off 1%; non-GAAP earnings up 27%; cash flow up 5%

|About: Myriad Genetics, Inc. (MYGN)|By:, SA News Editor

Myriad Genetics (NASDAQ:MYGN) fiscal Q2 results ($M): Total revenue: 194.0 (-1.3%); Hereditary cancer testing: 126.9 (-11.8%).

Net income: 32.1 (+444.1%); non-GAAP net income: 22.3 (+27.4%); EPS: 0.45 (+400.0%); non-GAAP EPS: 0.31 (+19.2%); cash flow ops: 33.0 (+5.1%).

Fiscal 2018 guidance: Revenue: $760M - 770M; EPS: $1.82 - 1.87; non-GAAP EPS: $1.11 - 1.16.

Fiscal Q4 guidance: Revenue: $186M - 188M; EPS: $0.11 - 0.13; non-GAAP EPS: $0.26 - 0.28.

Subscribe for full text news in your inbox